*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and Hong Kong Securities Clearing Company Limited ("**HKSCC**") take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated 28 May 2026 (the "**Prospectus**") of Lung Fung Group Holdings Limited (龍豐集團控股有限公司) (the "**Company**").*

This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the laws of Hong Kong). This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities of the Company. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Offer Shares.

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions. The Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933 as amended from time to time (the "**U.S. Securities Act**") or securities law of any state or other jurisdiction of the United States. The Offer Shares may not be offered, sold, pledged or otherwise transferred within the United States, except pursuant to an available exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. There will be no public offer of the Offer Shares in the United States. The Offer Shares are being offered and sold solely outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.*

龍豐集團
LUNG FUNG GROUP

Lung Fung Group Holdings Limited
龍 豐 集 團 控 股 有 限 公 司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2290)

END OF STABILISATION PERIOD, NO STABILISING ACTIONS AND LAPSE OF THE OVER-ALLOTMENT OPTION

The announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the laws of Hong Kong).

END OF STABILISATION PERIOD

The Company announces that the stabilisation period in connection with the Global Offering ended on Thursday, 2 July 2026, being the 30th day after the last day for lodging of applications under the Hong Kong Public Offering.

NO STABILISATION ACTIONS AND LAPSE OF OVER-ALLOTMENT OPTION

Reference is made to the announcement of the Company dated 4 June 2026. The Overall Coordinator (for itself and on behalf of the International Underwriters) confirmed that there had been no over-allocation of the Shares in the International Offering. Therefore, the Over-allotment Option had not been exercised and the Over-allotment Option lapsed on Thursday, 2 July 2026. The Company was informed by the Stabilizing Manager that no stabilising action was taken by the Stabilizing Manager or any person acting for it during the stabilisation period.

PUBLIC FLOAT

Immediately after the end of the stabilisation period, the Company complies and will continue to comply with the public float requirements under Rule 8.08 of the Listing Rules.

By Order of the Board
Lung Fung Group Holdings Limited
Tse Siu Hoi
Executive Director and Chairman of the Board

Hong Kong, 2 July 2026

As at the date of this announcement, Directors of the Company are: (i) Mr. Tse Siu Hoi and Ms. Tse Chui Ying as executive Directors; and (ii) Mr. Chu Woon Ming, Mr. Yau Sheung Yu and Ms. Woo Pui Yan Joyce as independent non-executive Directors.